Curevac N.V. (CVAC)

$4.16 +0.01 (0.24%)
Market Cap 960.17M
Revenue (ttm) 579.12M
Net Income (ttm) 175.50M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 30.30%
Debt to Equity Ratio 0.00
Volume 2,792,900
Avg Vol N/A
Day's Range N/A - N/A
Shares Out 224.34M
Stochastic %K N/A
Beta 1.77
Analysts Hold
Price Target $5.32

Company Profile

As of December 18, 2025, CureVac N.V. was acquired by BioNTech SE. CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human c...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 7071 9883 0
Address:
Friedrich-Miescher-Strasse 15, Tübingen, Germany
wheresdannynow
wheresdannynow Jul. 21 at 4:03 PM
$BVAXF The latest clinical update strengthens the scientific case for the DPX platform. $BIOV.CSE now needs regulatory execution, financing clarity and a development partner to unlock that value. $MRNA $BNTX $CVAC
0 · Reply
wheresdannynow
wheresdannynow Jul. 21 at 4:02 PM
$BVAXF $BIOV.CSE setup is binary but clear: promising human data on one side, financing and reporting risk on the other. Resolution of the filings could become as important as the next clinical announcement. $MRNA $CVAC
0 · Reply
wheresdannynow
wheresdannynow Jul. 20 at 4:35 PM
$BVAXF thesis is platform validation. If DPX can consistently generate durable, antigen-specific T-cell responses, the opportunity extends beyond a single cancer indication. $MRNA $BNTX $CVAC
0 · Reply
Davidendz
Davidendz Jul. 17 at 2:25 PM
$BVAXF Cancer vaccines have historically struggled with weak or short-lived immune activation. The $BIOV $BVAXF thesis rests on whether DPX can generate persistent, therapeutically relevant T-cell responses. $BNTX $MRNA $CVAC
0 · Reply
DocPharm
DocPharm Jan. 20 at 6:43 PM
$CVAC aye I just realized my shares converted to $BNTX Didn’t know it was happening that soon - sahhhwwwweeet
3 · Reply
khmerxbxboi
khmerxbxboi Dec. 26 at 3:23 AM
$CVAC = Santa Rally !!!
0 · Reply
OnlyFibs
OnlyFibs Dec. 26 at 1:41 AM
I'm following the footprints on $CVAC—the 10-day VWAP is finally turning into a launchpad. 🏗️⚡ Setup: Perfect 8h pivot bottom; RSI is waking up from the dead (31) meaning the spring is officially loaded. Unusual Flow: 13F filings show Citadel and Susquehanna shifting heavily into calls (+136%) as the merger floor solidifies. 🏗️ Target: Clearing the $4.37 wall triggers the gap-fill to the $6.83 bull targets. 📈 Safety: Stop below the $4.07 structural floor. 🧱 The BioNTech moat is absorbing the competition. Don't fight the $101.88 exchange reference price. 🚢📉 #hovdid
0 · Reply
G20Gains
G20Gains Dec. 25 at 2:51 PM
$CVAC Volatility reflects uncertainty about how effectively strategy converts into measurable outcomes. Cash flow visibility will determine how patient investors remain. A series of confirmed wins might reduce the required risk premium. In short, this remains an execution‑driven story with meaningful but conditional upside.
0 · Reply
OnlyFibs
OnlyFibs Dec. 24 at 12:51 AM
$CVAC: One Last Momentum Play? 🎯 Action: Up +2.18% today as liquidity dries up ahead of the Jan buyout Catalyst: Compulsory acquisition in Jan 2026 will clean up remaining 13.2% of float Support: Rock solid at $3.80; Bulls holding the red trendline PT: Fair value sitting near the $5.43 analyst median for those still holding RSI is screaming oversold—watch for a final liquidity grab before it’s gone. 🔋💎 #hovdid
0 · Reply
khmerxbxboi
khmerxbxboi Dec. 23 at 8:05 PM
$CVAC = $$$
0 · Reply
Latest News on CVAC
CureVac sues Moderna for patent infringement over COVID-19 vaccines

Apr 24, 2026, 4:52 PM EDT - 3 months ago

CureVac sues Moderna for patent infringement over COVID-19 vaccines

MRNA

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

Dec 3, 2025, 9:01 AM EST - 8 months ago

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

BNTX

CureVac Announces Voting Results of Extraordinary General Meeting

Nov 25, 2025, 7:05 PM EST - 8 months ago

CureVac Announces Voting Results of Extraordinary General Meeting

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates

Nov 24, 2025, 7:30 AM EST - 8 months ago

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates

CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates

Aug 15, 2025, 7:50 AM EDT - 1 year ago

CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates

CureVac settles patent dispute litigation with Pfizer and BioNTech

Aug 7, 2025, 9:00 PM EDT - 1 year ago

CureVac settles patent dispute litigation with Pfizer and BioNTech

BNTX PFE

CureVac Announces Voting Results of General Meeting

Jun 24, 2025, 4:35 PM EDT - 1 year ago

CureVac Announces Voting Results of General Meeting

Top Stock Movers Now: Oracle, Boeing, CureVac, and More

Jun 12, 2025, 12:05 PM EDT - 1 year ago

Top Stock Movers Now: Oracle, Boeing, CureVac, and More

BA ORCL

BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising.

Jun 12, 2025, 7:11 AM EDT - 1 year ago

BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising.

BNTX

BioNTech to acquire CureVac in $1.25 billion all-stock deal

Jun 12, 2025, 7:03 AM EDT - 1 year ago

BioNTech to acquire CureVac in $1.25 billion all-stock deal

BNTX

CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates

May 20, 2025, 7:15 AM EDT - 1 year ago

CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates

CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE

May 15, 2025, 4:45 PM EDT - 1 year ago

CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

Apr 10, 2025, 7:30 AM EDT - 1 year ago

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025

Apr 8, 2025, 7:25 AM EDT - 1 year ago

CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer

Apr 7, 2025, 7:15 AM EDT - 1 year ago

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer

CureVac Shares Rise on Patent Confirmation Amid BioNTech Lawsuit

Mar 28, 2025, 12:45 PM EDT - 1 year ago

CureVac Shares Rise on Patent Confirmation Amid BioNTech Lawsuit

BNTX

European Patent Office declares CureVac mRNA patent valid

Mar 27, 2025, 6:22 PM EDT - 1 year ago

European Patent Office declares CureVac mRNA patent valid

CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

Mar 27, 2025, 4:30 PM EDT - 1 year ago

CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top Innovators

Feb 18, 2025, 7:15 AM EST - 1 year ago

CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top Innovators

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

Nov 12, 2024, 7:20 AM EST - 1 year ago

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

Nov 7, 2024, 7:30 AM EST - 1 year ago

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

Nov 4, 2024, 7:20 AM EST - 1 year ago

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

CureVac to Present at the 12th International mRNA Health Conference

Nov 4, 2024, 7:15 AM EST - 1 year ago

CureVac to Present at the 12th International mRNA Health Conference

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Oct 28, 2024, 8:10 AM EDT - 1 year ago

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents

Oct 8, 2024, 5:50 AM EDT - 1 year ago

Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents

BNTX PFE

CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress

Sep 13, 2024, 8:15 AM EDT - 2 years ago

CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program

Sep 12, 2024, 7:15 AM EDT - 2 years ago

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

Sep 9, 2024, 7:15 AM EDT - 2 years ago

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update

Aug 15, 2024, 7:30 AM EDT - 2 years ago

CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update

CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma

Aug 15, 2024, 7:20 AM EDT - 2 years ago

CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma

CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board

Aug 15, 2024, 7:15 AM EDT - 2 years ago

CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board

CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech

Jul 11, 2024, 7:15 AM EDT - 2 years ago

CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech

Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer

Jul 11, 2024, 7:00 AM EDT - 2 years ago

Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer

GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines

Jul 3, 2024, 10:18 AM EDT - 2 years ago

GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines

GSK

CureVac's stock soars on GSK's $1.56 billion deal for its COVID-19 and flu vaccines

Jul 3, 2024, 7:53 AM EDT - 2 years ago

CureVac's stock soars on GSK's $1.56 billion deal for its COVID-19 and flu vaccines

GSK

GSK and CureVac to Restructure Collaboration into New Licensing Agreement

Jul 3, 2024, 2:40 AM EDT - 2 years ago

GSK and CureVac to Restructure Collaboration into New Licensing Agreement

GSK

CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities

Jul 3, 2024, 2:40 AM EDT - 2 years ago

CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities

GSK buys full rights to make COVID, influenza vaccines from CureVac

Jul 3, 2024, 2:26 AM EDT - 2 years ago

GSK buys full rights to make COVID, influenza vaccines from CureVac

GSK

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update

Apr 24, 2024, 7:30 AM EDT - 2 years ago

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer

Apr 24, 2024, 7:20 AM EDT - 2 years ago

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer

CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK

Apr 24, 2024, 7:20 AM EDT - 2 years ago

CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK

CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024

Apr 18, 2024, 7:15 AM EDT - 2 years ago

CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024

CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines

Apr 16, 2024, 7:15 AM EDT - 2 years ago

CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines

CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK

Apr 4, 2024, 7:15 AM EDT - 2 years ago

CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK

CureVac stock gains as COVID vaccine candidates show promise

Jan 5, 2024, 7:59 AM EST - 2 years ago

CureVac stock gains as COVID vaccine candidates show promise

CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform

Jan 5, 2024, 7:30 AM EST - 2 years ago

CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform

CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

Dec 19, 2023, 9:35 AM EST - 2 years ago

CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update

Nov 14, 2023, 7:30 AM EST - 2 years ago

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update

CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK

Nov 1, 2023, 8:15 AM EDT - 2 years ago

CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK

wheresdannynow
wheresdannynow Jul. 21 at 4:03 PM
$BVAXF The latest clinical update strengthens the scientific case for the DPX platform. $BIOV.CSE now needs regulatory execution, financing clarity and a development partner to unlock that value. $MRNA $BNTX $CVAC
0 · Reply
wheresdannynow
wheresdannynow Jul. 21 at 4:02 PM
$BVAXF $BIOV.CSE setup is binary but clear: promising human data on one side, financing and reporting risk on the other. Resolution of the filings could become as important as the next clinical announcement. $MRNA $CVAC
0 · Reply
wheresdannynow
wheresdannynow Jul. 20 at 4:35 PM
$BVAXF thesis is platform validation. If DPX can consistently generate durable, antigen-specific T-cell responses, the opportunity extends beyond a single cancer indication. $MRNA $BNTX $CVAC
0 · Reply
Davidendz
Davidendz Jul. 17 at 2:25 PM
$BVAXF Cancer vaccines have historically struggled with weak or short-lived immune activation. The $BIOV $BVAXF thesis rests on whether DPX can generate persistent, therapeutically relevant T-cell responses. $BNTX $MRNA $CVAC
0 · Reply
DocPharm
DocPharm Jan. 20 at 6:43 PM
$CVAC aye I just realized my shares converted to $BNTX Didn’t know it was happening that soon - sahhhwwwweeet
3 · Reply
khmerxbxboi
khmerxbxboi Dec. 26 at 3:23 AM
$CVAC = Santa Rally !!!
0 · Reply
OnlyFibs
OnlyFibs Dec. 26 at 1:41 AM
I'm following the footprints on $CVAC—the 10-day VWAP is finally turning into a launchpad. 🏗️⚡ Setup: Perfect 8h pivot bottom; RSI is waking up from the dead (31) meaning the spring is officially loaded. Unusual Flow: 13F filings show Citadel and Susquehanna shifting heavily into calls (+136%) as the merger floor solidifies. 🏗️ Target: Clearing the $4.37 wall triggers the gap-fill to the $6.83 bull targets. 📈 Safety: Stop below the $4.07 structural floor. 🧱 The BioNTech moat is absorbing the competition. Don't fight the $101.88 exchange reference price. 🚢📉 #hovdid
0 · Reply
G20Gains
G20Gains Dec. 25 at 2:51 PM
$CVAC Volatility reflects uncertainty about how effectively strategy converts into measurable outcomes. Cash flow visibility will determine how patient investors remain. A series of confirmed wins might reduce the required risk premium. In short, this remains an execution‑driven story with meaningful but conditional upside.
0 · Reply
OnlyFibs
OnlyFibs Dec. 24 at 12:51 AM
$CVAC: One Last Momentum Play? 🎯 Action: Up +2.18% today as liquidity dries up ahead of the Jan buyout Catalyst: Compulsory acquisition in Jan 2026 will clean up remaining 13.2% of float Support: Rock solid at $3.80; Bulls holding the red trendline PT: Fair value sitting near the $5.43 analyst median for those still holding RSI is screaming oversold—watch for a final liquidity grab before it’s gone. 🔋💎 #hovdid
0 · Reply
khmerxbxboi
khmerxbxboi Dec. 23 at 8:05 PM
$CVAC = $$$
0 · Reply
khmerxbxboi
khmerxbxboi Dec. 22 at 4:59 PM
$CVAC = Sleeping ...
0 · Reply
taxplanr
taxplanr Dec. 19 at 11:39 AM
$BNTX and now all the trials will also have to show there is no shedding for approval Add more expenses for failure ​on top of $CVAC losses
0 · Reply
khmerxbxboi
khmerxbxboi Dec. 17 at 6:53 PM
$CVAC = loading time my friends !!!
0 · Reply
Tom2772
Tom2772 Dec. 16 at 9:31 PM
$CVAC The P/E ratio will show its potential for improvement through synergies as early as next year. Most importantly, there will be no more internal legal disputes and 1,000 new patents for $BNTX . CureVac's expertise should help BioNTech get closer to the approval of mRNA-based cancer therapies. They are just one step away. This is a major undertaking, and I am convinced it will be worth significantly more than $1.25 billion in the long run.
1 · Reply
taxplanr
taxplanr Dec. 11 at 2:45 PM
$BNTX maybe it was just a bad time to take on more overhead and operational losses with $CVAC 🤔
0 · Reply